
The Duke Comprehensive Parkinson’s Disease and Movement Disorders Clinic conducts a variety of clinical trials. Leading clinical trials is an important part of our mission to continually seek out better treatments and cures for those affected by movement disorders. Trials for the following conditions are currently available. If you believe you have one of these conditions and would like to participate, click on the links below to answer brief screening questions and express your interest in participating.
Dystonia
- Writer's Cramp Dystonia - This clinical trial is testing the use of non-invasive brain stimulation to improve symptoms of writer's cramp dystonia. Take this short survey to see if you are eligible to participate.
- Dystonia Biomarkers - This study hopes to identify blood "signatures" that indicate dystonia. The knowledge gained from this exploratory study may help improve diagnosis, identify subsets of dystonias that may respond to differing treatments, and/or create new opportunities to evaluate disease progression or treatment response. Take this short survey to see if you are eligible to participate.
Essential Tremor
- JAZZ - This study is testing an investigational drug called JZP385 for treating moderate to severe essential tremor when compared to a placebo. Participation will last for around 21 weeks. Take this short survey to see if you are eligible to participate.
Huntington's Disease
-
ENROLL-HD - This is an interest form for an observational study for patients with Huntington's disease and their families. Take this short survey to see if you are eligible to participate.
Multiple System Atrophy
- Synuclein-One -This study is testing to see if small skin biopsies can effectively detect diseases. The skin biopsy test may provide an easily accessible and cost-effective diagnostic test. There is one research visit involving a skin biopsy and other examination tasks. Take this short survey to see if you are eligible to participate.
Parkinson's Disease
- TEMPO - This trial is evaluating the effectiveness of tavapadon, a novel, once-daily dopamine agonist medication for the treatment of early Parkinson's disease. This study involves multiple visits over the course of 26 weeks. Participants are randomly assigned to receive 5 mg of tavapadon daily, 15 mg of tavapadon daily, or placebo. After the initial 26 weeks, all participants will have the option to receive tavapadon treatment. Take this short survey to see if you are eligible to participate.
- TOPAZ - This trial is testing if a bone-strengthening drug called zoledronic acid can help prevent debilitating hip fractures in Parkinson's disease. Participation involves one in-home nurse visit for medication administration and follow-up telephone calls every several months for up to 5 years. Take this short survey to see if you are eligible to participate.
-
wAID-PD -This is a web-based automated imaging study. Along with those who have Parkinson’s Disease, people with PSP and MSA are considered for this study. There are 2 visits. One visit will include a questionnaire and an MRI scan and another will take place 12-18 months after the first visit as a follow-up. Take this short survey to see if you are eligible to participate.